The specter of tariffs is likely to overshadow what was a positive quarter for J&J. The company’s adjusted earnings rose 2.2% ...

Johnson & Johnson's first-quarter revenue and profit exceeded Wall Street expectations, driven by strong cancer drug sales. The company raised its 2025 sales forecast, factoring in the acquisition of ...

Johnson & Johnson has reported a strong first-quarter performance, surpassing Wall Street expectations and showcasing the power of its oncology portfolio. The company's revenue and profit both ...

Biocon Biologics Ltd (BBL), the biosimilars company and subsidiary of Biocon Ltd, has announced a licence agreement with Regeneron to commercialise Yesafili, a drug used to treat ophthalmological ...

On an adjusted basis, the company earned $2.77 per share in the quarter, 2.2 per cent higher than the previous year and above analysts' estimates of $2.59 per share ...

Johnson & Johnson today reported first-quarter revenue and profit above Wall Street estimates, driven again by strong sales of its cancer treatments including multiple myeloma medicine Darzalex.

Johnson & Johnson is holding its earnings outlook steady despite President Donald Trump moving decisively toward imposing ...

Johnson & Johnson raised its sales outlook for the year even as it prepares to face new headwinds from President Trump’s tariff campaign.New tariffs, primarily on medical technology products, are ...

New results from a subgroup analysis of the ICONIC-LEAD study showed icotrokinra was effective and safe for the treatment of moderate to severe plaque psoriasis in adolescents, according to a press ...

Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.

Johnson & Johnson (NYSE:JNJ), on Tuesday, reported a first-quarter 2025 adjusted EPS of $2.77, up 2.2% year over year, beating the consensus of $2.60. The pharmaceutical giant reported sales of $21.89 ...

Delgocitinib cream is efficacious and well-tolerated for the treatment of adults with chronic hand eczema for up to 52 weeks.